First biosimilar adalimumab – SB5
Authors:
Lukáš M.
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F., a. s., Praha
Published in:
Gastroent Hepatol 2018; 72(6): 551-552
Category:
Sources
1. Lee N, Lee JJ, Yang H et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs 2018; 1– 16. doi: 10.1080/ 19420862.2018.1530920.
2. Frampton JE. SB5: An adalimumab biosimilar. BioDrugs 2018; 32(5): 507– 510. doi: 10.1007/ s40259-018-0307-0.
3. Weinblatt ME, Baranauskaite A, Dokoupilova E et al. Switching from reference adalimumab to SB5 (Adlimumab biosimilar) in patients with reumatoid arthritis: fifty-two-week phase 3 randomized study results. Arthritis Rheumatol 2018; 70(6): 832– 840. doi: 10.1111/ irv.40444.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2018 Issue 6
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Metamizole in the Treatment of Acute Postoperative Pain
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Most read in this issue
- Meckel’s diverticulum as a cause of abdominal emergency
- Hepatopathy as the first manifestation of systemic AL amyloidosis
- Wilson’s disease in childhood – two case reports
- News of pharmacological treatment of obesity